undamentalytics Newsletter
Sign in

Transcode Therapeutics, Inc. (RNAZ) stock

Add to watchlist

Add holding +

NASDAQ: RNAZ Nasdaq Biotechnology

Transcode Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds3 adding, 2 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 1331% in the quarter to 2024-12-31.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Transcode Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 97% and a beta of 0.8 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$1286.15 against an average estimate of -$89.88: missed by 1331.0%
Share reaction
-3.7% in the first session after the results on April 5, 2024, against +1.1% for the S&P 500

Transcode Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week-4.5%
  • 1 month+3.8%
  • This year-76.1%
  • 1 year-85.4%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
April 5, 2024

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Agreement
  3. Announcement
  4. Leadership
  5. Governance
  6. Shareholder vote
  7. Governance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Transcode Therapeutics, Inc. valuation models and calculator

No model value for Transcode Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Transcode Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 12.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.65 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Transcode Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Transcode Therapeutics, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Dec 2024 −$89.88 −$1286.15 −1331.0%
Sept 2024 −$452.76 −$147.84 +67.3%
Jun 2024 −$21436.81 −$27350.42 −27.6%
Mar 2024 −$25872.02 −$600.60 +97.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
0.3%
of tradable shares
Days to cover
1.03
at average volume
Short interest, 1 month
−10%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
1.8%
of shares
Employees
12
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
RNAZ−74%−99%−99%−93%−76%
Industry peers (median)−56%−17%−28%−5%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
RNAZ25%8%25%42%27%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
RNAZ−89%−99%−99%−98%−88%
S&P 500−25%−10%−8%−19%−9%

Worst fall since July 8, 2021: 100% from July 12, 2021 to October 1, 2026. Getting back needed a 308597958% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.54 – $12.34
From 52-week high
−86.8%
vs 50-day average
−9.9%
vs 200-day average
−73.3%
Volatility (1 year)
97%
Beta vs S&P 500
0.79

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±9.8%
After a week
3 up, 9 down
typical move ±18.1%
After a month
1 up, 11 down
typical move ±26.7%
Results releasedNext dayS&P 500 next day5 days21 days
April 5, 2024 −3.7% +1.1% −8.7% +19.9%
January 16, 2024 −56.8% −0.9% −84.3% −86.0%
November 14, 2023 −10.9% +2.2% −28.6% −47.5%
March 31, 2023 +4.5% +1.8% +13.4% −3.0%
February 17, 2023 −5.8% −2.3% −5.2% −32.7%
February 1, 2023 −12.1% +2.5% −29.4% −38.7%
November 14, 2022 +4.4% 0.0% −7.6% −13.0%
August 15, 2022 +3.1% +0.6% −7.0% −10.9%
May 16, 2022 −4.9% +1.6% −11.1% −43.6%
April 1, 2022 +0.7% +1.1% +5.2% −4.5%
November 15, 2021 −1.4% +0.4% −8.1% −16.6%
August 23, 2021 +9.2% +1.0% +9.2% −3.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$208,059
Institutions reporting
8
Shares held vs prior quarter
▲ 8.6%
Positions opened / closed
2 / 1

Top buyers and sellers, Q2 2026: 3 institutions bought and 2 sold ; the biggest buyer was Yorkville Advisors Global, LP (+20K shares) and the biggest seller Geode Capital Management, LLC (−13K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Yorkville Advisors Global, LP $121,958 20K 58.6% New
Vanguard Capital Management LLC $40,644 7K 19.5% 0.0%
Vanguard Fiduciary Trust Co $18,518 3K 8.9% 0.0%
UBS Group AG $17,934 3K 8.6% ▼ 65.2%
FMR LLC $4,384 1K 2.1% New
Tower Research Capital LLC (TRC) $4,204 1K 2.0% ▲ 196.9%
Wells Fargo & Company $342 0K 0.2% 0.0%
Sbi Securities Co., Ltd. $75 0K 0.0% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Transcode Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around June 24, 2024 estimated from the company's past filing pattern, not announced

  • April 5, 2024
  • January 16, 2024
  • November 14, 2023
  • March 31, 2023
  • February 17, 2023
  • February 1, 2023

Recent SEC filings

Data status

When each part of this page on Transcode Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Transcode Therapeutics, Inc. in brief

What does Transcode Therapeutics, Inc. do?
Transcode Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Transcode Therapeutics, Inc.'s stock ticker?
Transcode Therapeutics, Inc. trades under the ticker RNAZ on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Transcode Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Yorkville Advisors Global, LP, Vanguard Capital Management LLC and Vanguard Fiduciary Trust Co. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.